secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0000950103-23-011755
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA confirms PRGN-2012 Phase 1/2 study as pivotal for accelerated approval; cash runway into 2025
--------------------------------------------------------------------------------

- FDA confirmed ongoing Phase 1/2 single-arm study of PRGN-2012 for RRP as pivotal for accelerated approval; no placebo trial needed.
- Retired all outstanding convertible notes in Q2; cash, equivalents, and investments totaled $95.6M as of June 30, 2023.
- Q2 2023 loss from continuing operations was $20.3M ($0.08/share), improved from $26.1M loss in Q2 2022.
- SG&A expenses decreased 27% Q2 vs prior year; revenue fell 39% due to reduced services at Exemplar.
- Projected cash runway into 2025; Phase 2 enrollment complete, data collection by Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010323011755/0000950103-23-011755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010323011755/dp198223_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-23-011755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer